In the middle of September, the large-cap list OMXC25 was at record levels. But since then, there has been a spanner in the works. With Friday's decline of 1.2 percent, the year's gain had been erased and landed with a flop at minus 0.2 percent.
A heavy burden is Novo Nordisk. In September, the pharmaceutical company's enormous success with diabetes and obesity medicine was estimated to account for half of Denmark's growth this year.
But in three months, the company has fallen 23.4 percent. The reason is setbacks in research studies and competition fears among investors, writes Dagens industri.
It didn't get better when incoming President Donald Trump on Thursday nominated vaccine critic Robert F Kennedy junior as the US Health Minister.
The next day, Novo Nordisk fell 5.4 percent in Copenhagen, and vaccine manufacturer Bavarian Nordic – also weighed down by weak quarterly figures – plummeted over 17 percent.
But despite the recent influenza, Novo Nordisk still has a market value of approximately 5,000 billion Swedish kronor – nearly ten times more than the next largest Danish listed company – and over ten years, the stock has soared 445 percent.
